{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:07:23Z","timestamp":1785812843485,"version":"3.56.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Intensity-modulated radiation therapy (IMRT) and alternative chemotherapy regimens strive to maintain efficacy while minimizing toxicity in locally advanced head and neck cancer (LAHNC) treatment. Our experience with concurrent IMRT and taxane-based chemotherapy is presented.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>A retrospective review of 150 consecutive patients with LAHNC treated with IMRT and concurrent taxane-based chemotherapy with curative intent was performed. The IMRT fractionation regimen consisted of 69.3 Gy to gross disease (2.1 Gy\/fraction) and 56.1 Gy to prophylactic nodal sites (1.7 Gy\/fraction). Weekly paclitaxel (30 mg\/m2) and carboplatin (area under the concentration\u2013time curve [AUC], 1) were given concurrently to all patients, and 69% received weekly induction with paclitaxel (60 mg\/m2) and carboplatin (AUC, 2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Over 90% of patients received the prescribed radiation dose. Ninety-six percent completed five or more cycles of concurrent chemotherapy, with similar tolerability for induction chemotherapy. A percutaneous endoscopic gastrostomy (PEG) tube was required in 80 patients, with 10 maintaining PEG use &amp;gt;18 months. Acute grade 4 mucositis and dermatitis developed in 2.0% and 4.0% of patients, respectively. No patient experienced nadir sepsis, grade \u22653 late xerostomia, or significant nephropathy or gastrointestinal toxicity. Median follow-up was 30 months. The 3-year locoregional control rate was 83.2% with disease-free survival and overall survival rates of 78.8% and 76.5%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Rates of acute and late toxicities were low, with excellent radiation dose delivery and impressive tumor control at 3 years, suggesting that concurrent carboplatin and paclitaxel with IMRT is a reasonable therapeutic option for the curative treatment of LAHNC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0396","type":"journal-article","created":{"date-parts":[[2012,5,2]],"date-time":"2012-05-02T04:01:14Z","timestamp":1335931274000},"page":"673-681","source":"Crossref","is-referenced-by-count":18,"title":["Intensity-Modulated Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer: Toxicities and Efficacy"],"prefix":"10.1093","volume":"17","author":[{"given":"Gregory","family":"Vlacich","sequence":"first","affiliation":[{"name":"a Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Diaz","sequence":"additional","affiliation":[{"name":"a Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Thorpe","sequence":"additional","affiliation":[{"name":"a Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"b Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"},{"name":"f Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndee","family":"Kirby","sequence":"additional","affiliation":[{"name":"a Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Sinard","sequence":"additional","affiliation":[{"name":"c Department of Otolaryngology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"},{"name":"f Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Shakhtour","sequence":"additional","affiliation":[{"name":"e Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shyr","sequence":"additional","affiliation":[{"name":"e Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Murphy","sequence":"additional","affiliation":[{"name":"g Sarah Cannon Cancer Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Netterville","sequence":"additional","affiliation":[{"name":"c Department of Otolaryngology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"},{"name":"f Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendell G.","family":"Yarbrough","sequence":"additional","affiliation":[{"name":"c Department of Otolaryngology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"},{"name":"d Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"},{"name":"f Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Cmelak","sequence":"additional","affiliation":[{"name":"a Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA"},{"name":"f Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,1]]},"reference":[{"key":"2021122308161789600_B1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"2021122308161789600_B2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"2021122308161789600_B3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update of 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021122308161789600_B4","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122308161789600_B5","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122308161789600_B6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122308161789600_B7","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2005.05.3629","article-title":"Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?","volume":"24","author":"Adelstein","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122308161789600_B8","first-page":"60","article-title":"Carboplatin in the treatment of squamous cell head and neck cancers","volume":"19","author":"Aisner","year":"1992","journal-title":"Semin Oncol"},{"key":"2021122308161789600_B9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0360-3016(00)00408-9","article-title":"The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck","volume":"47","author":"Suntharalingam","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.cco.0000158735.91723.0e","article-title":"Taxanes in the treatment of head and neck cancer","volume":"17","author":"Schrijvers","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"2021122308161789600_B11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hed.20522","article-title":"Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: Results of a phase II multi-institutional trial","volume":"29","author":"Cmelak","year":"2007","journal-title":"Head Neck"},{"key":"2021122308161789600_B12","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2007.10.8951","article-title":"Phase II trial of chemoradiation for organ preservation in resectable stage III and IV squamous cell carcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group Study E2399","volume":"25","author":"Cmelak","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308161789600_B13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1634\/theoncologist.12-5-555","article-title":"Intensity-modulated radiation therapy for head and neck carcinoma","volume":"12","author":"Gr\u00e9goire","year":"2007","journal-title":"The Oncologist"},{"key":"2021122308161789600_B14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hed.20332","article-title":"Intensity-modulated radiation therapy in head and neck cancers: An update","volume":"29","author":"Lee","year":"2007","journal-title":"Head Neck"},{"key":"2021122308161789600_B15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0360-3016(02)03940-8","article-title":"Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer","volume":"55","author":"Chao","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0360-3016(99)00550-7","article-title":"Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer","volume":"46","author":"Dawson","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijrobp.2003.10.032","article-title":"Recurrences near base of skull after IMRT for head-and-neck cancer: Implications for target delineation in high neck and for parotid gland sparing","volume":"59","author":"Eisbruch","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial","volume":"12","author":"Nutting","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122308161789600_B19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0167-8140(01)00449-2","article-title":"Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: A comparison with conventional techniques","volume":"61","author":"Chao","year":"2001","journal-title":"Radiother Oncol"},{"key":"2021122308161789600_B20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0360-3016(99)00247-3","article-title":"Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer","volume":"45","author":"Eisbruch","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1368-8375(00)00063-4","article-title":"Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy","volume":"37","author":"Henson","year":"2001","journal-title":"Oral Oncol"},{"key":"2021122308161789600_B22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijrobp.2006.06.013","article-title":"Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial","volume":"66","author":"Pow","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B23","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.ijrobp.2004.05.050","article-title":"Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they be spared by IMRT?","volume":"60","author":"Eisbruch","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B24","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.ijrobp.2007.02.049","article-title":"Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: Early dose-effect relationships for the swallowing structures","volume":"68","author":"Feng","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B25","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2009.24.6199","article-title":"Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: Clinical and functional results","volume":"28","author":"Feng","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308161789600_B26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2003.09.011","article-title":"CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines","volume":"69","author":"Gr\u00e9goire","year":"2003","journal-title":"Radiother Oncol"},{"key":"2021122308161789600_B27","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0360-3016(01)01544-9","article-title":"Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy\u2014results of a multicentric randomized German trial in advanced head-and-neck cancer","volume":"50","author":"Staar","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B28","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1056\/NEJM199806183382503","article-title":"Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer","volume":"338","author":"Brizel","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122308161789600_B29","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1200\/JCO.2000.18.7.1458","article-title":"Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial","volume":"18","author":"Jeremic","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122308161789600_B30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijrobp.2003.08.004","article-title":"Intensity-modulated radiation therapy for oropharyngeal carcinoma: Impact of tumor volume","volume":"59","author":"Chao","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/cncr.23578","article-title":"Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma","volume":"113","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"2021122308161789600_B32","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/hed.21120","article-title":"Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: A retrospective single-institution analysis","volume":"31","author":"Saba","year":"2009","journal-title":"Head Neck"},{"key":"2021122308161789600_B33","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ijrobp.2006.06.040","article-title":"A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma","volume":"66","author":"Lee","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308161789600_B34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hed.20700","article-title":"Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group phase II study (HN-53)","volume":"30","author":"Chougule","year":"2008","journal-title":"Head Neck"},{"key":"2021122308161789600_B35","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122308161789600_B36","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122308161789600_B37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/COC.0b013e3182019ee3","article-title":"Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck","volume":"35","author":"Ready","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"2021122308161789600_B38","first-page":"393a","article-title":"Carboplatin and Taxol as induction therapy for locally advanced carcinoma of the head and neck","volume":"17","author":"Dang","year":"1998","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0396","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0396","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/5\/673\/41859142\/oncolo_17_5_673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/5\/673\/41859142\/oncolo_17_5_673.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T20:56:45Z","timestamp":1640293005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/5\/673\/6403357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,1]]},"published-print":{"date-parts":[[2012,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0396","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,5,1]]},"published":{"date-parts":[[2012,5,1]]}}}